The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGeiger Counter Regulatory News (GCL)

Share Price Information for Geiger Counter (GCL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 56.90
Bid: 56.00
Ask: 57.80
Change: 1.00 (1.79%)
Spread: 1.80 (3.214%)
Open: 56.00
High: 56.90
Low: 56.00
Prev. Close: 55.90
GCL Live PriceLast checked at -
Geiger Counter is an Investment Trust

To deliver attractive returns to shareholders principally in the form of capital growth, through investment in companies involved in the exploration, development and production of uranium to supply the nuclear power industry.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GCL MONTHLY FACT SHEET MARCH 2024

26 Apr 2024 14:15

RNS Number : 2599M
Geiger Counter Ltd
26 April 2024
 

 

 

Geiger Counter Limited Plc 

 

Monthly Investor Report - March

 

The full monthly factsheet is now available on the Company's website and a summary can be found below. 

 

NCIM - Geiger Counter Ltd - Fund Page for Geiger Counter Ltd

 

 

Enquiries: 

 

For the Investment Manager 

CQS (UK) LLP 

Craig Cleland 

0207 201 5368 

For the Company Secretary and Administrator 

BNP Paribas S.A., Jersey Branch 

Dean Plowman/Ann-Marie Pereira 

01534 813 967/ 01534 709198 

 

----------------------------------------------------------------------- 

 

 

Fund Description 

 

The objective of the Geiger Counter Fund is to provide investors with the potential for capital growth through investment primarily in the securities of companies involved in the exploration, development and production of energy, predominantly within the uranium industry. Up to 30% of the value of the Company's investment portfolio may be invested in other resource-related companies from outside the energy sector.

 

Portfolio Managers 

 

Keith Watson and Robert Crayfourd 

 

 

Key Advantages for the Investor 

· Access to mining assets in the uranium sector

· May benefit from embedded subscription share

· Low correlation to major asset classes

 

 

Key Fund Facts1 

 

 

Total Gross Assets 

£105.6m 

Reference Currency 

GBP 

Ordinary Shares: 

Net Asset Value 

71.30p 

Mid-Market Price  

50.0p 

Net gearing4 

15.97% 

Discount 

(29.87%) 

 

 

Ordinary Share and NAV Performance2 

 

 

One Month 

Three Months 

One Year 

Three Years 

Five Years 

 

(%) 

(%) 

(%) 

(%) 

(%) 

NAV 

4.30 

6.31 

70.74 

106.79 

278.05 

Share Price 

(6.02) 

(7.41) 

35.14

31.58 

162.12 

 

 

Commentary3 

 

After its strong run into mid-February, the U3O8 (Uranium) price consolidated during March with the spot price ending the month 6.6% lower at $88.25/lb. However, uranium-related equities proved resilient and the Fund NAV increased 4.3%, compared to a 3.3% sterling return registered by the Solactive Uranium Pure Play Index. Since March month-end, more widespread reporting of flooding in Kazakhstan has raised concerns of supply disruption from the largest Uranium producing country. However, melt waters have primarily affected river systems in the north of the country rather than the primary uranium producing operations located in the south. As such, potential disruption may be more administrative, though we believe this nevertheless highlights supply risks resulting from a such concentrated number of producers.

 

Sector news remains supportive. Notably, countries attending the Nuclear Power Summit,

organised by the International Atomic Anergy Association, all backed plans for a wider adoption of nuclear power as a key source of base load power. Positive comments on the sector from the CEO of US nuclear power operator, Constellation, formerly part of Exelon, typifies sentiment towards Nuclear energy. The industry appears to benefit from bipartisan political support, helpful state and federal policies, and increased customer demand for reliable and clean energy. We believe this provides confidence to underpin the industry's growth via existing reactor life extensions and incremental reactor development. Encouragingly, European producer Urenco also announced it had commenced construction work as part of its previously announced enrichment supply expansion plans.

 

Calls for a relaxation on the uranium mining ban in Western Australia by Australia's Chamber of Commerce could be a precursor to some progress on economic projects that are currently prevented from being developed. Such efforts could also be adopted by other nations, such as the US, that are seeking to encourage much needed domestic U3O8 production and to reduce nuclear fuel supply chain risks. This could benefit investments, such as Laramide and IsoEnergy, which have assets in states which currently prevent uranium mining.

 

The largest contributors to performance were Canadian mine developer Nexgen and ASX-listed Paladin, whose share prices both rose over 10% in sterling terms over the month. Both companies provided positive updates on their projects. IsoEnergy also announced plans to reopen its small, and already permitted, Tony M mine in Utah during 2025. Ur-Energy announced its first shipment of uranium from its restarted Lost Creek project and also indicated that it would expand its fully permitted and licensed Shirley Basin Project in Wyoming. This helped drive a recovery in the position that had weakened mid-month.

 

We believe the Fund is well placed to grow with the up-coming issuance of embedded 1 for 5 rights, at an issue price of 37.74p, due towards the end of April.

 

 

Gross Leverage6

(%)

Commitment Leverage7

(%)

Geiger Counter Ltd 

116

116 

 

 

CQS (UK) LLP

4th Floor, One Strand, London WC2N 5HR, United Kingdom

T: +44 (0) 20 7201 6900 | F: +44 (0) 20 7201 1200

 

CQS (US), LLC

152 West 57th Street, 40th Floor, New York, NY 10019, US

T: +1 212 259 2900 | F: +1 212 259 2699

 

Tavistock Communications

18 St. Swithin's Lane, London EC4N 8AD

T: +44 20 7920 3150 | geigercounter@tavistock.co.uk

 

Sources: 1R&H Fund Services (Jersey) Limited, as at the last business day of the month indicated at the top of this report. 2R&H Fund Services Limited/DataStream, as at the last business day of the month indicated at the top of this report, total return performance net of fees and expenses based on bid prices. These include historic returns and past performance is not a reliable indicator of future results. The value of investments can go down as well as up. Please read the important legal notice at the end of this document. 3Market data sourced from Bloomberg unless otherwise stated. The Fund may since have exited some or all of the positions detailed in the commentary. 4 BMO, UxC, Company data September 2023. 5 www.eia.gov. 6CQS, as at the last business day of the month indicated at the top of this report. For methodology details see Article 4(3) of Directive 2011/61/EU (AIFMD) and Articles 6, 7, 9 and 10 of Delegated Regulation 231/2013. 7CQS, as at the last business day of the month indicated at the top of this report. For methodology details see Article 4(3) of Directive 2011/61/EU (AIFMD) and Articles 6, 8, 9, 10 and 11 of Delegated Regulation 231/2013.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DOCQKABPBBKDQQB
Date   Source Headline
7th May 20245:30 pmRNSNet Asset Value(s)
7th May 20241:30 pmRNSNotification in regard to Subscription Rights
7th May 20241:15 pmRNSResult of subscription rights exercise
3rd May 20242:20 pmRNSNet Asset Value(s)
2nd May 20242:45 pmRNSNet Asset Value(s)
1st May 20243:35 pmRNSNet Asset Value(s)
30th Apr 20243:30 pmRNSNet Asset Value(s)
30th Apr 20242:00 pmRNSShare Buyback
29th Apr 202412:45 pmRNSNet Asset Value(s)
29th Apr 202412:30 pmRNSShare Buyback
26th Apr 20242:15 pmRNSGCL MONTHLY FACT SHEET MARCH 2024
26th Apr 202412:15 pmRNSNet Asset Value(s)
26th Apr 202412:00 pmRNSShare Buyback
25th Apr 20242:45 pmRNSNet Asset Value(s)
25th Apr 20242:00 pmRNSShare Buyback
24th Apr 20242:40 pmRNSNet Asset Value(s)
24th Apr 20241:30 pmRNSShare Buyback
23rd Apr 20243:30 pmRNSNet Asset Value(s)
23rd Apr 20241:45 pmRNSShare Buyback
22nd Apr 20243:35 pmRNSNet Asset Value(s)
22nd Apr 20241:30 pmRNSShare Buyback
19th Apr 20242:35 pmRNSNet Asset Value(s)
18th Apr 20241:35 pmRNSNet Asset Value(s)
17th Apr 202412:20 pmRNSNet Asset Value(s)
16th Apr 20245:20 pmRNSNet Asset Value(s)
15th Apr 202412:50 pmRNSNet Asset Value(s)
12th Apr 20241:35 pmRNSNet Asset Value(s)
11th Apr 20241:15 pmRNSNet Asset Value(s)
10th Apr 20243:40 pmRNSNet Asset Value(s)
9th Apr 20241:25 pmRNSNet Asset Value(s)
8th Apr 20241:10 pmRNSNet Asset Value(s)
5th Apr 20242:05 pmRNSNet Asset Value(s)
4th Apr 20241:10 pmRNSNet Asset Value(s)
3rd Apr 20242:40 pmRNSNet Asset Value(s)
3rd Apr 20249:00 amRNSInvestment Manager Acquisition
2nd Apr 20243:50 pmRNSNet Asset Value(s)
28th Mar 20241:50 pmRNSNet Asset Value(s)
27th Mar 20241:00 pmRNSNet Asset Value(s)
27th Mar 20249:33 amRNSNotification to Shareholders - Subscription Rights
26th Mar 20242:55 pmRNSNet Asset Value(s)
25th Mar 20241:00 pmRNSNet Asset Value(s)
22nd Mar 20244:45 pmRNSPotential listing on the London Stock Exchange
22nd Mar 20241:15 pmRNSNet Asset Value(s)
21st Mar 20241:25 pmRNSNet Asset Value(s)
20th Mar 20242:30 pmRNSNet Asset Value(s)
19th Mar 20244:45 pmRNSNet Asset Value(s)
18th Mar 20241:45 pmRNSNet Asset Value(s)
15th Mar 202411:35 amRNSNet Asset Value(s)
14th Mar 202412:45 pmRNSNet Asset Value(s)
13th Mar 20242:15 pmRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.